Bristol Myers Squibb (BMY) Gains from Investment Securities (2010 - 2026)

Bristol Myers Squibb (BMY) has 17 years of Gains from Investment Securities data on file, last reported at -$21.0 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$21.0 million, down 320.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $590.0 million (up 11900.0% YoY), and the FY2025 annual result was $351.0 million, changed N/A from the prior year.
• Gains from Investment Securities retreated to -$21.0 million in Q1 2026 per BMY's latest filing, from $275.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $336.0 million in Q2 2025 and troughed at -$269.0 million in Q3 2023.
• A 5-year average of $23.8 million and a median of -$5.0 million in 2025 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities surged 690.91% in 2023, then tumbled 475.0% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$44.0 million in 2022, then surged by 690.91% to $260.0 million in 2023, then tumbled by 108.85% to -$23.0 million in 2024, then jumped by 1295.65% to $275.0 million in 2025, then slumped by 107.64% to -$21.0 million in 2026.
• Business Quant data shows BMY's Gains from Investment Securities at -$21.0 million in Q1 2026, $275.0 million in Q4 2025, and $336.0 million in Q2 2025.